Purinergic signalling in systemic sclerosis.
fibrosis
purines
systemic sclerosis
vasculopathy
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
06 07 2022
06 07 2022
Historique:
received:
15
10
2021
revised:
09
11
2021
accepted:
10
11
2021
pubmed:
2
12
2021
medline:
9
7
2022
entrez:
1
12
2021
Statut:
ppublish
Résumé
SSc is a chronic autoimmune rheumatic disease that involves numerous organs and presents major management challenges. The histopathologic hallmarks of SSc include vasculopathy, fibrosis and autoimmune phenomena involving both innate and adaptive immune systems. Purinergic signalling is a pathway that may be implicated in the pathophysiology of several of these disease manifestations. Extracellular purines are potent signalling mediators, which have been shown to be dysregulated in SSc. As examples, purines can exacerbate vasculopathy and provoke platelet dysfunction; as well as contributing to immune dysregulation. Elements of purinergic signalling further promote organ and tissue fibrosis in several disease models. Here, we provide an overview of extracellular purine metabolism in purinergic signalling and link disorders of these to the molecular pathology of SSc. We also discuss targeting the purinergic signalling and explore the translational applications for new therapeutic options in SSc.
Identifiants
pubmed: 34849624
pii: 6438027
doi: 10.1093/rheumatology/keab859
doi:
Substances chimiques
Purines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2770-2782Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.